Co-Diagnostics
Update in progressCODX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and sells nucleic-acid–based reagents and PCR testing platforms for point-of-care and at-home use. Its portfolio includes PCR tests for COVID-19, influenza, TB, hepatitis B/C, HPV, malaria, chikungunya, dengue, and Zika; multiplex panels for mosquito-borne diseases; tools for infectious-disease detection, cancer liquid biopsy, and agricultural genomics; and a portable PCR device. Founded 2013, based in Salt Lake City.
Company score
- Sentiment
- -0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- -0.24
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!